The first human therapeutic clinical trial involving GenVec’s adenoviral-vacor technology used in an HIV vaccine candidate will be conducted by the Vaccine Research Center (VRC), a part of NIAID. The randomized, placebo-controlled study will measure safety and immunogenicity in 15 HIV positive patients.

The trial will combine two components, a DNA prime vaccine and GenVec’s adenovector-based technology used in the boost vaccine. Patients in the study will be treated with the first vaccine (the DNA prime) followed by a booster with the second vaccine (rAD5 boost) and will be evaluated for 48 weeks.

Previous articleMonsanto to Acquire Delta and Pine Land Company
Next articleSchering-Plough and Xenogen Embark on Target Validation Collaboration